Antimeningococcal Protection in Patients Receiving Terminal Complement Inhibitors
Although guidelines recommend vaccination alone, our findings indicate that combined protection offers substantially greater protection against IMD in patients receiving long-term C5i. Continued prospective monitoring will be essential to define the optimal preventive strategies in this high-risk population.
Authors
- Tanja Kersnik Levart
- Víctor Pérez-Beltrán
- Franz Schaefer (ORCID: https://orcid.org/0000-0001-7564-9937)
- Sandra Habbig (ORCID: https://orcid.org/0000-0002-6511-5023)
- Anne‐Laure Sellier‐Leclerc (ORCID: https://orcid.org/0000-0001-9902-0850)
- Jonas Hofstetter (ORCID: https://orcid.org/0000-0001-6328-9575)
- Aleksandra Vujović
- Olivia Boyer (ORCID: https://orcid.org/0000-0002-3957-1359)
- Maria Cristina Mancuso (ORCID: https://orcid.org/0009-0007-8610-5266)
- Mattia Parolin
Institutions
- Hôpital Necker-Enfants Malades (FR)
- University of Padua (IT)
- University of Ljubljana (SI)
- University of Cologne (DE)
- Université Paris Cité (FR)
- Heidelberg University (DE)
- Ljubljana University Medical Centre (SI)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Hospices Civils de Lyon (FR)
- Vall d'Hebron Hospital Universitari (ES)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1016/j.ekir.2025.11.025
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alexion Pharmaceuticals
- Inozyme Pharma
- European Commission
- Deutsche Forschungsgemeinschaft
- Angelini Pharma
- Akershus Universitetssykehus
- European Rare Kidney Disease Reference Network
- Samsung